Research and Markets: Pharmaceutical Opportunities in Emerging Markets - Newly Industrialized Asia

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/980533/opportunities_in_e) has announced the addition of Decision Resources, Inc.'s new report "Opportunities in Emerging Markets - Newly Industrialized Asia (South Korea, Singapore, Taiwan, and Hong Kong SAR)" to their offering.

What opportunities are available for pharmaceutical companies to pursue in the newly industrialized Asian economies (NIEs), compared with the emerging and developing economies of BRIC-MT? Owing to the rapid growth of many Asian economies, most pharmaceutical companies are taking a long hard look at Asia-Pacific markets to chart a course toward increasing global and regional drug sales. What information does a company use when deciding to choose one country market over another? This report investigates the NIE markets and compares these markets with the advanced economies of the United States and Japan and with the emerging and developing BRIC-MT markets. It explores the differences and similarities between these diverse markets and discusses strategies as well as opportunities for pharmaceutical companies in NIEs.

Questions Answered in this Report:

  • There is no one-size-fits-all strategy for accessing Asia-Pacific markets, which are heterogeneous and offer diverse advantages and disadvantages. What are the key characteristics of NIE markets? How do these markets compare with emerging and developing BRIC-MT markets? How do they compare with the advanced markets of Japan and the United States?
  • Trade barriers can limit the ability of imported products to compete in domestic markets in NIE and BRIC-MT economies. What recent free trade agreement (FTA) was ratified with South Korea? What other FTAs are in process? What are the likely impacts of these agreements on the pharmaceutical industry?
  • Pfizer created an established products unit in 2009. Why does Pfizer view established products as a key element of the company's growth and risk diversification strategy? Why is Pfizer's approach to unlocking value in new markets for existing drugs especially useful in the developed economies of the NIE countries?
  • Eisai has embarked on a bold new mid-term strategic plan called Hayabusa. How does Eisai plan to change its business model? What is Eisai's East Asia (Japan, China, Thailand, South Korea, Hong Kong) strategy?
  • Bayer has designated the Asia-Pacific region as a key growth and investment opportunity. What is Bayer's two-pronged approach for this region? Which markets is Bayer targeting for more investment?

Scope of the Report:

  • Geographies: Emerging markets; BRIC-MT; newly industrialized Asian economies (NIEs), including Singapore, Taiwan (Province of China), Hong Kong Special Administrative Region (SAR), and Republic of Korea (South Korea); advanced economies, including Japan, United States, and EU; ASEAN-5, including Indonesia, Malaysia, Philippines, Thailand, and Vietnam; developing Asia, including China, India, and ASEAN-5; East Asia, including Japan, China, Thailand, South Korea, Hong Kong; Macau.
  • Economic development: Global competition, economic growth, KORUS free trade agreement, Trans-Pacific Partnership (TPP) agreement, EU-South Korea free trade agreement, North American Free Trade Agreement (NAFTA), Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.
  • NIE versus BRIC-MT market comparisons: Global competitive index, population, gross domestic product (GDP), GDP per capita, health expenditures, infant mortality, life expectancy, labor force pay and productivity, labor force female-to-male ratio, quality of math and science education, prevalence of trade barriers, number of clinical trials, intellectual property protection, foreign ownership of companies, favoritism on decisions by government officials, utility patents, intensity of local competition, extent of market dominance, financial services, local equity markets, venture capital.
  • Products: Biosimilars, cancer diagnostics, pharmacogenomics, vaccines, established products, branded generics, innovative brands, embedded biomarkers.
  • Pharmaceutical strategies: Innovation, maximizing the value of established products, globalization, pharmaceutical market expansion, maximizing regional sales, joint ventures, strategic partnerships, diversification, operational scale, licensing, research agreements, nonprofit research alliances, regional headquarters, distribution and commercialization partners, global clinical trials, divestment, pharmaceutical manufacturing, risk diversification, portfolio expansion, value creation, Hayabusa mid-term strategic plan, personalized medicine, Japan-United States-European-centric business model, globalization-emerging-markets-centric model.
  • Expert insight:Peter Wittner provides insights on free trade agreements and company activities in South Korea. Mr. Wittner is the principal of Interpharm Consultancy and specializes in generics strategies. Previously, he worked at Ranbaxy (U.K.), H.N. Norton (subsequently part of Ivax), Evans Medical, A.H. Robins, and Koppel & Co. in general management, business development, and sales and marketing.
  • Exhibits: 17 data-rich tables and figures.

Companies Mentioned:

To view the full list and to purchase this extensive report, click the link below

http://www.researchandmarkets.com/research/980533/opportunities_in_e



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Asia Pacific

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.